This excerpt taken from the EXEL 8-K filed Aug 5, 2008.
Q2 2008 Highlights
This excerpt taken from the EXEL 8-K filed Feb 21, 2006.
In 2005, we made tremendous strides in our effort to make cancer therapies with the potential to have a positive impact on patients lives. We have eight compounds in ongoing clinical trials and we anticipate sharing additional clinical data this year at several medical meetings said George A. Scangos, Ph.D., president and chief executive officer of Exelixis.
In 2006, we will continue to focus our efforts on moving compounds rapidly into and through the clinic, while efficiently managing our financial resources, continued Dr. Scangos.
This excerpt taken from the EXEL 8-K filed Nov 3, 2005.
Third Quarter 2005 Highlights
Development: We continued to make significant advances in our clinical programs. We initiated three phase 1 clinical trials and now have a total of eight compounds in clinical development, as well as three compounds in preclinical development. We are pleased with the progress of the trials and the enrollment rates. All of the compounds are of high quality and each is directed to a different spectrum of targets. Importantly, the third quarter marks our entry into a new phase where we will be able to begin to discuss our clinical data publicly. Abstracts from our three lead internally-developed cancer compounds were accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting in Philadelphia, and we are excited about the opportunity to discuss these data. Highlights for the quarter include the following:
Financing: In August, we raised net proceeds of $49.6 million through the issuance of 6.5 million shares of common stock pursuant to a shelf registration statement to support our ongoing research and development activities.
For additional details on our compounds please visit our website at www.exelixis.com under the heading Pipeline.
2005 is an unprecedented year for Exelixis. Our ability to advance 8 compounds through clinical development, including one compound in phase 3 testing and three compounds that will soon move to phase 2 is a strong validation of our entire process from target identification through clinical development, and reflects our continued ability to execute, said George A. Scangos, Ph.D. president and chief executive officer of Exelixis. The first four orally
administered compounds to enter the clinic all exhibit good oral bioavailability and appropriate half-lives. I am excited about the quality and number of compounds in the pipeline, and I believe that the reasons for our enthusiasm will become evident as we are able to share the data, as we will begin to do at the upcoming AACR-NCI-EORTC meeting. Our solid financial position is a reflection of the cash that we have brought in from a variety of sources this year, and enables us to aggressively move our pipeline forward. I believe that we are crossing an inflection point and that 2005 marks the beginning of a new, clinically-focused era for Exelixis.